Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) just unveiled an update.
Genflow Biosciences has appointed Gad Berdugo as Independent Non-Executive Chairman, a move aimed at accelerating the company’s corporate development and R&D strategy as it advances its gene-therapy programs for age-related diseases. Berdugo’s three decades of experience in global biotech business development, U.S. capital markets and RNA-based therapeutics, including lipid nanoparticle delivery, are expected to strengthen Genflow’s scientific platform, expand its U.S. and global presence, and support the company as it enters a new development phase with key data readouts and a sharpened focus on high-potential programs, while existing director Tamara Joseph remains on the board to ensure governance continuity.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Spark’s Take on GB:GENF Stock
According to Spark, TipRanks’ AI Analyst, GB:GENF is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.
To see Spark’s full report on GB:GENF stock, click here.
More about Genflow Biosciences Plc
Genflow Biosciences Plc is a UK-headquartered, European-based biotechnology company with R&D facilities in Belgium, focused on pioneering gene therapies to decelerate the aging process and address age-related diseases. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is being evaluated in a 12-month proof-of-concept clinical trial in aged dogs, with additional plans to study its potential in treating MASH, a prevalent chronic liver disease lacking effective therapies.
Average Trading Volume: 1,673,370
Technical Sentiment Signal: Buy
Current Market Cap: £9.13M
See more data about GENF stock on TipRanks’ Stock Analysis page.